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Human transforming growth factor α (TGF-α) is digested
to a smaller (1–43), less biologically active, form in
acidic gastric juice
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Background: Transforming growth factor α (TGF-α) is a 50 amino acid peptide with potent prolifera-
tive and cytoprotective activity present in gastric mucosa and juice.
Aims: To determine the forms and biological activity of natural and recombinant TGF-α following incu-
bation with acid pepsin.
Patients: Human gastric juice was obtained under basal conditions from patients taking acid suppres-
sants and from volunteers undergoing intragastric neutralisation.
Methods: Samples were analysed using mass spectroscopy and/or high pressure liquid chromatogra-
phy with radioimmunoassay. Biological activity was determined using thymidine incorporation into rat
hepatocytes and an indomethacin/restraint induced gastric damage rat model.
Results: TGF-α1–50 is cleaved to TGF-α1–43 by acid pepsin and this is the predominant form in normal
gastric juice. However, intragastric neutralisation or taking acid suppressants caused the predominant
form to be TGF-α1–50. TGF-α1–43 had only half of the ability to maximally stimulate [3H]thymidine incorpo-
ration into primary rat hepatocytes (28 177 (1130) DPM/well for 2.16 nM TGF-α1–43 v 63 184 (3536)
DPM/well for TGF-α1–50; p<0.001). A similar reduced potency was seen when used in an indomethacin
induced rat gastric damage model (0.18 µmol/kg/h of TGF-α1–43 reduced ulcer area by 19% whereas
TGF-α1–50 reduced area by 62%; p<0.001).
Conclusions: TGF-α1–50 is cleaved to the TGF-α1–43 form by acid pepsin, causing 2–5-fold loss of bio-
logical activity. Such changes may have relevance to the actions of acid suppressants and the import-
ance of this peptide in both normal and abnormal growth.
Transforming growth factor α (TGF-α) is a 50 amino acidpeptide present in gastric juice and throughout thegastrointestinal tract.1 It is a potent stimulant of
proliferation of several gastrointestinal cell lines in vitro2–5 and
in the rat intestine when given systemically.6 In addition,
TGF-α protects against injury in a variety of gastric damaging
models such as those induced by ethanol or stress,7 8 and
human gastric juice concentrations of TGF-α increase in
response to administration of noxious agents such as
indomethacin.9 Taken together, these studies suggest TGF-α
plays a role in growth, differentiation, and maintenance of
mucosal integrity of the bowel.
As TGF-α is present in human gastric juice, it is constantly
bathed in acid and pepsin. There has been virtually no work
however examining whether it is adversely affected by being
present in such a harsh environment. We therefore examined
the effect of acid and pepsin on the form and biological activ-
ity of TGF-α in vitro and in vivo and determined the forms of
TGF-α present in gastric juice obtained from subjects under
varying acidic conditions.
MATERIAL AND METHODS
Materials
Recombinant and purified native human TGF-α were ob-
tained from Calbiochem (Nottingham, UK). Porcine pepsin
was obtained from Sigma (P6887, Poole, UK) in the form of a
lyophilised powder. All other chemicals were obtained from
Sigma unless stated otherwise
Methods of analyses of samples to determine the forms
of TGF-α
Preparation of gastric juice samples prior to high pressure
liquid chromatography (HPLC)
Samples of gastric juice which were to have HPLC performed
were first concentrated using octadecylsilane (C18) cartridge
chromatography, as described by Elson and colleagues.10
Eluates were then dried on a centrifugal evaporator (Savant;
Farmingdale, New York, USA) and resuspended in 0.1%
trifluoroacetic acid (TFA) prior to injection into the HPLC loop.
Reverse phase HPLC
Studies involving reverse phase HPLC used a Hewlett Packard
1100 (Stockport, UK) consisting of a quaternary pump deliv-
ery system, Rheodyne-7725 sample injector, and a 1 ml injec-
tion loop. The column used was an analytical “Jupiter” C5, 300
A, 5 µm (4.6×150 mm) column (Phenomenex UK Ltd). After
application of the sample, the column was eluted isocratically
(15% acetonitrile (AcN), 0.1% TFA) for 10 minutes before a
gradient from 15–40% AcN, 0.1% TFA was run over 30
minutes. Samples were collected on a Foxy-Jr fraction collec-
tor and the system was controlled by a HP pentium PC with
HP chemstation software. Samples were dried on a centrifugal
evaporator and resuspended in water or Tris buffer prior to
mass spectroscopy or radioimmunoassay, respectively.
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Radioimmunoassay (RIA) for TGF-α
TGF-α-like immunoreactivity was measured using a commer-
cial RIA kit (BT-350; Biomedical Technologies Inc., Stoughton,
Massachusetts, USA). Briefly, tubes were incubated for 24 hours
at 4°C, and bound and free TGF-α were separated using 50
µl/tube of donkey antisheep antibody and 50 µl of PEG followed
by mixing and centrifugation at 2000 rpm for 15 minutes at 4°C.
Typical results gave a maximal binding ratio (Tmax tubes) of 0.5
and a non-specific binding ratio (To tubes) of 0.03. Sensitivity of
the assay is 0.02 ng/tube. This radioimmunoassay does not cross
react with epidermal growth factor (EGF).
Pilot study to determine the effect of acid pepsin digestion of
TGF-á on immunoreactivity of TGF-á
Six aliquots of TGF-α were randomised to be incubated in
either Tris buffer (pH 7) or 0.1 M HCl, each containing pepsin
at 1 mg/ml, for one hour at 37°C. At the end of the incubation
period all samples were neutralised using 0.1 M NaOH.
Standard curves were then performed using all of these aliq-
uots on a single day. Data were analysed by fitting three
parameter logistic functions of loge concentration by least
squares. These showed a small but significant decrease in the
immunoreactivity of TGF-α which had been treated with acid
pepsin. Fifty per cent of maximal binding occurred at a
concentration of 5.2 ng/ml TGF-α in Tris/pepsin standards and
2.0 ng/ml TGF-α in standard which had been treated with acid
pepsin (significance of difference between 50% maximum
binding values p<0.001). Concentrations of TGF-α in gastric
juice samples were determined taking into account these
small differences in immunoreactivity of the intact and
digested forms.
Mass spectroscopy
Molecular weight was assessed by mass spectroscopy using
the technique of matrix assisted laser desorption time of flight
with a Finnigan LaserMAT mass spectrophotometer (San
Jose, California, USA). Samples were mixed with 0.5 µl of
alpha-cyano-4-hydroxycinnamic acid matrix (1% in 50% AcN,
0.1% TFA). Standards used were oxidised insulin β chain
(molecular weight 3496.9) and ubiquitin (molecular weight
8564.9). Our group have previously validated this technique
for use in peptide sequence analyses.11
Methods of analyses of biological activity
In vitro assay
Background to method
Primary rat hepatocytes provide a robust reproducible method
for determining the biological activity of EGF-like molecules.
We have previously used this method to compare and contrast
the relative bioactivity of different EGF receptor ligands.12 The
methodology is therefore described only briefly below.
Isolation and culture of hepatocytes
Hepatocytes were isolated from male Wistar rats by in situ
collagenase perfusion and cultured in Williams E medium
using the method of Selden and Hodgson.13 Preliminary stud-
ies showed that the addition of Tris buffer alone, pepsin in Tris
buffer, or acid and pepsin (which was subsequently neutral-
ised) to the hepatocytes had no effect on their function, as
determined by basal thymidine uptake, or their ability to
respond to a standard dose of TGF-α added to the wells. Cell
viability, determined by the ability to exclude 0.2% trypan
blue, was greater than 80% in all experiments.
Thymidine incorporation
To assess the percentage of cells entering DNA synthesis,
[3H]thymidine (2 µCi/well, 10 µl; Amersham International,
Bucks, UK) was included in the cultures eight hours after the
addition of test samples. The amount of [3H]thymidine incorpo-
rated was assessed biochemically, 18 hours after addition of
thymidine.13 Cells were washed for 15 seconds with water using
a Dynatech Multimash automatic cell harvester and solubilised
by incubation at 37°C for one hour in 200 µl of 1 M KOH. Cell
extract (50 µl) was counted in a β counter in 1 ml of scintillant
(Optiphase Safe; LKB-Pharmacia, Bromma, Sweden).
Assay of biological activity of different forms of TGF-α in
vivo
The ability of TGF-α to prevent gastric damage by indometh-
acin and restraint in rats was assessed using previously
validated methods.14 Under light ether anaesthesia, rats (male
Sprague Dawley, 225–250 g) had two subcutaneous cannula
inserted into the back of the neck and were then placed in
Bullman restraint cages. Once the animals had recovered, a
continuous subcutaneous infusion of saline or various doses
and forms of TGF-α was started at 1 ml/h using a
multi-syringe infusion pump (Harvard Apparatus, Massachu-
setts, USA). Thirty minutes later, 20 mg/kg of indomethacin
were injected subcutaneously via the second cannulae.
Animals were killed by stunning and cervical dislocation three
hours later and their stomachs removed and inflated with 4 ml
of 10% formalin. The next day the stomachs were opened and
placed in fresh formalin prior to assessment. The stomachs
were randomly coded and all analyses of gastric damage were
assessed blind. Total ulcerated area (mm2/stomach) was
assessed using a dissecting microscope (×10) with the aid of a
square grid. The stomachs were then embedded in wax and
the depth of damage assessed microscopically and given a
microscopic ulcer score, as previously described.15 Using this
system, each stomach was given a score of 0 to 4, with 0=no
damage, 1=one small erosion (less than 0.5 mm), 2=two
small or one large erosion (greater than 0.5 mm), 3=two or
more large erosions, and 4=any area of ulceration extending
to the muscularis mucosa.
Ethics approval
Local ethics approval was obtained for studies involving
human volunteers and subjects gave informed consent.
Study protocols
Study 1: stability of recombinant TGF-α in acid pepsin in
vitro
Aliquots of 10 µg of recombinant TGF-α were incubated in
various solutions for one hour at 37°C. These were: (a) isotonic
saline; (b) 0.1 M HCl; (c) Tris buffer (pH 7.4) containing
1 mg/ml of pepsin; and (d) 0.1 M HCl containing 1 mg/ml of
pepsin. All assay conditions were performed in quadruplicate.
One of the samples from each condition was assessed using
mass spectroscopy without further separation. The other three
samples underwent HPLC. Following HPLC separation, each
fraction was split into two. One half of the fraction was
analysed by RIA and the other by mass spectroscopy. In addi-
tion, to ensure the biological relevance of our studies, 5 µg
aliquots of purified human TGF-α were incubated for one
hour in saline or HCl plus pepsin and analysed in an identical
fashion.
To determine how fast the digestion of TGF-α occurred in
acid pepsin, 5 µg of recombinant TGF-α were incubated in
1 ml of acid pepsin at 37°C for 10 minutes; this was then
immediately neutralised to pH 7 using NaOH and analysed as
above.
Study 2: form of TGF-α present in normal human acidic
and neutral gastric juice
Baseline gastric juice samples were obtained by aspiration
from patients who had a nasogastric tube inserted for clinical
reasons. Samples from six patients taking proton pump
inhibitors (PPIs) for clinical reasons were compared with
samples obtained from six control patients. pH was deter-
mined for all samples to ensure control samples had a pH of 3
or less and PPI samples had a pH of more than 4. Samples were
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screened for the presence of trypsin (using a standard
spectrophometric method employing Nα-benzoyl-DL-arginine-
p-nitroanilide) and bilirubin to ensure there was no contami-
nation by pancreatic proteases. Samples that contained no
detectable trypsin or bilirubin were frozen and stored at −20°C
prior to HPLC and RIA.
Study 3: changes in the form of intragastric TGF-α in
response to intragastric neutralisation
Seven subjects took part in this study (six males, one female).
After an overnight fast, a double lumen nasogastric tube was
placed for continuous aspiration from the gastric antrum with
infusion 20 cm proximally. For six subjects, the study
comprised a 40 minute perfusion period with normal saline
followed by 40 minutes of perfusion with 0.17 M sodium
bicarbonate. The seventh subject had an 80 minute perfusion
period with saline alone. Perfusion was at 5 ml/min and all
perfusates contained 5 g/l of polyethylene glycol 4000 (subse-
quently assayed using a standard turbidometric method) to
allow for correction for duodenal losses. Aspirates were
collected continuously on ice into a beaker containing a pH
electrode to allow the juice to be continuously titrated to pH 7
using NaOH. Samples were mixed thoroughly and stored in 10
minute batches. At the midpoint of each collection period, a
1 ml sample was collected directly from the aspiration tubing
to allow analysis of pH and pepsin activity. Neutralised
samples which contained no detectable trypsin or bilirubin
were frozen and stored at −20°C prior to HPLC and RIA.
Study 4: biological effects of changes in the form of
TGF-α
Preparation of TGF-á
To determine the effect of acid pepsin digestion on the
biological activity of TGF-α, four aliquots of 100 µg of
previously pooled recombinant TGF-α were randomly allo-
cated to be incubated for one hour at 37°C in either 1 ml of 0.1
M HCl containing 1 mg pepsin (that would be expected to
digest TGF-α) or 1 ml of Tris buffer pH 7.0 containing 1 mg
pepsin (that would not be expected to digest TGF-α). At the
end of the incubation period, the stock solutions were
neutralised to pH 7. Samples were separated by HPLC as
previously described and fractions containing TGF-α1–43 and
TGF-α1–50 identified by mass spectroscopy. Protein concentra-
tions of the fractions were determined using a Biorad protein
assay and samples were then diluted in Tris buffer containing
1 mg/ml bovine serum albumin to minimise adhesion to the
container during storage. These solutions were then used to
perform studies examining changes in bioactivity.
In vitro assay
Various concentrations (0–9 nM) of either intact TGF-α (Tris/
pepsin treated) or the acid pepsin treated TGF-α were added to
the hepatocytes and thymidine incorporation determined 26
hours later. For both intact and acid pepsin treated TGF-α,
each dose of TGF-α was measured in quadruplicate in four
separate wells.
In vivo gastric damaging study
Rats were randomised to receive saline (containing bovine
serum albumin 0.2 mg/ml), “intact” TGF-α (Tris-pepsin
treated TGF-α) at either 0.18 or 0.90 µmol/kg/h , or acid pep-
sin treated TGF-α at either 0.18 or 0.90 µmol/kg/h.
Statistics
Data from the hepatocyte assay were analysed using the Prism
2.0 computer package. Analysis of variance followed by t test-
ing was carried out: p<0.05 was taken as significant.
The gastric damaging model was analysed using analysis of
variance followed by t testing based on the mean square error
and degrees of freedom obtained from the analysis of
variance, as appropriate: p<0.05 was taken as significant.
RESULTS
Study 1: stability of recombinant TGF-α in acid pepsin
in vitro
Intact recombinant TGF-α, purified TGF-α, TGF-α which had
been incubated in HCl without pepsin, and Tris pepsin treated
TGF-α gave a single peak on mass spectroscopy corresponding
to intact TGF-α1–50. Measured mass was always in the range
5546–5554 (expected molecular weight of TGF-α 5546). In
samples that were further analysed by performing HPLC
followed by RIA, a single peak of immunoreactivity was found
in fraction 14 (fig 1A). Mass spectroscopy of aliquots of this
fraction also gave a mass corresponding to TGF-α1–50.
Figure 1 Stability of transforming growth factor α (TGF-α) in acid
and pepsin determined by reverse phase high pressure liquid
chromatography and radioimmunoassay. TGF-α incubated in buffer
(shown) or HCl alone (not shown) eluted as a single peak in fraction
14 (A). TGF-α that had been preincubated in acid and pepsin for 10
minutes eluted as two peaks equating to a mixture of TGF-α1–43
(fractions 11 and 12) and TGF-α1–50 (B). Incubation for a prolonged
period (60 minutes) resulted in elution of a single peak equating to
TGF-α1–43 (C).
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TGF-α which had been incubated for one hour in acid pepsin
analysed by mass spectroscopy without HPLC separation gave
one peak corresponding to TGF-α1–43 (measured molecular
weight 4796, theoretical molecular weight 4796). HPLC separa-
tion followed by RIA showed one peak of immunoreactivity in
fractions 11 and 12 (fig 1C). Mass spectroscopy of aliquots of
these fractions also gave a mass corresponding to TGF-α1–43.
Following 10 minutes of incubation of TGF-α with acid
pepsin, approximately 40% of TGF-α remained intact (fig 1B)
with 60% of TGF-α being in the TGF-α1–43 form. TGF-α
incubated in acid alone resulted in a peak in fraction 14 indi-
cating intact TGF-α1–50 (as in fig 1A). Studies using native
purified TGF-α gave similar results (data not shown)
Study 2: form of TGF-α present in normal acidic and
neutral gastric juice
Gastric juice samples from control patients (pH <3) gave one
peak corresponding to TGF-α1–43, which eluted in fractions 11
and 12, when analysed by HPLC and RIA. Gastric juice
samples collected from two patients taking PPIs (pH >4)
resulted in one peak in fractions 11 and 12, corresponding to
TGF-α1–43. However, gastric juice samples collected from four
patients taking PPIs (pH >4) resulted in a split peak eluting in
fractions 12 and 14, corresponding to TGF-α1–43 and TGF-α1–50,
respectively, with approximately 40% of TGF-α eluting in the
intact form. Total gastric juice TGF-α concentrations from the
various subgroups were similar, giving a pooled value of 186
(41–839) ng/l (median (interquartile range)).
Study 3: changes in the forms of intragastric TGF-α in
response to intragastric neutralisation
Subjects receiving saline infusion all had a gastric pH of
between 1.8 and 3.0. Prior to and during saline infusion, gas-
tric samples showed that virtually all of the TGF-α eluted from
the HPLC column in the position of TGF-α 1–43 (fig 2A).
During bicarbonate perfusion, the pH of the samples were
all in the range 6.8–7.2 and the peak of TGF-α-LI corre-
sponded to TGF-α1–50 with a slight shoulder in the position of
TGF-α1–43 (fig 2B). The subject who had saline perfusion
throughout showed no change in the form of TGF-α present
during the final period (TGF-α1–43).
Study 4: biological activity assays
[3H]Thymidine uptake into primary rat hepatocytes
Both forms of TGF-α stimulated thymidine uptake in hepato-
cytes in a dose dependant manner (fig 3). However, maximal
Figure 2 Influence of gastric pH on the forms of transforming
growth factor α (TGF-α) present in gastric juice. TGF-α present in
resting normal gastric juice (pH <3) or collected during a saline
wash eluted from high pressure liquid chromatography as a single
peak in fractions 11 and 12, corresponding to TGF-α1–43 (A).
Changing the intragastric infusate to sodium bicarbonate caused the
pH to rise to approximately 7 and the predominant form of TGF-α in
the juice to be the 1–50 form (fraction 14) (B).
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Figure 3 Effect of acid pepsin pretreatment on the biological
activity of transforming growth factor α (TGF-α) using hepatocytes as
a bioassay. Recombinant TGF-α1–50 was pretreated by incubation in
either pepsin in neutral Tris buffer (preserving the 1–50 form) or acid
pepsin (causing digestion to the 1–43 form), followed by
neutralisation. The biological activity of the samples were then
compared by determining their ability to stimulate [3H]thymidine
incorporation into primary rat hepatocytes. Each concentration was
tested in quadruplicate. Acid pepsin treated TGF-α (TGF-α1–43) only
resulted in 50% of the maximal stimulation of intact TGF-α
(TGF-α1–50). For all doses studied, biological activity was greater for
the TGF-α1–50 form versus the same dose of TGF-α1–43 (p<0.01 for all
doses greater than 0.54 nM).
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Figure 4 Effect of acid pepsin pretreatment on the biological
activity of transforming growth factor α (TGF-α) using attenuation of
gastric damage as bioassay. Samples were treated as described in
fig 3. Intact TGF-α (TGF-α1–50) or acid pepsin treated TGF-α (TGF-α1–43)
was infused in various doses into animals that were restrained and
given indomethacin (20 mg/kg). The mean surface area of damage
(SEM) (mm2/stomach) is shown for each dose. Animals receiving
intact TGF-α had less gastric damage than those receiving acid
pepsin treated TGF-α (p<0.001); n=6–8 per group.
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stimulation by TGF-α1–50 was approximately double that
caused by TGF-α1–43 (76447 (5654) v 35375 (2710) DPM/well
for 9 nM). For all doses studied, biological activity was greater
for the TGF-α1–50 form compared with the same dose of
TGF-α1–43 (p<0.01 for all doses greater than 0.54 nM)
Gastric damaging model
Both forms of TGF-α decreased the amount of gastric damage
in a dose dependent manner compared with the control
(saline) group (fig 4). Analysis of variance showed a
significant effect of both the dose (F1,29=13.238, p=0.0000)
and form (F1,29=20.597, p=0.000) of TGF-α. For both doses
tested, TGF-α1–50 was significantly more potent than the TGF-
α1–43 form in its ability to reduce injury (p<0.01, see fig 4).
Assessment using the microscopic damage score gave similar
results (data not shown). An absolute quantitative compari-
son of the relative potencies of the two forms of TGF-α is not
possible in this study. However, the area of damage seen in
animals receiving 0.9 µmol/kg/h of the TGF-α1–43 was slightly
higher than that seen in animals receiving 0.18 µmol /kg/h of
TGF-α1–50 suggesting that, in this particular model, the intact
form is about 3–5 times as potent as TGF-α1–43.
DISCUSSION
We have shown that TGF-α is susceptible to cleavage by acid
pepsin in vivo and in vitro. Under normal basal acidic
conditions, the predominant form in gastric juice is TGF-α1–43
but following intragastric neutralisation or in most patients
taking clinically relevant doses of PPIs, the predominant form
in gastric juice becomes the full length (TGF-α1–50) form. We
have also shown that the acid pepsin digested TGF-α1–43 has
about half to one fifth of the biological activity of the intact
TGF-α1–50 molecule.
Mass spectroscopy provides a rapid sensitive method of
determining the molecular weight of test peptides and is
capable of demonstrating minor “clipping” of peptides which
are not seen using simple size exclusion analyses. Mass spec-
troscopy is however not quantitative and is less useful in ana-
lysing peptides in complex biological solutions which may
contain multiple peptides of similar molecular weight. We
therefore used it in conjunction with HPLC and RIA to deter-
mine qualitative and quantitative changes in the forms of
TGF-α.
For the in vitro studies, a variety of cells of gastrointestinal
origin were available. Carcinoma cell lines of colonic (for
example, HT29) or gastric (for example, AGS) origin have pre-
viously been used by us and other groups to assess prolifera-
tive and antiproliferative activity of various peptides. These
cells have the advantage of being derived from the human
gastrointestinal epithelium and being relatively easy to
culture. However, they also have the disadvantages of being
obtained from carcinoma cell lines and, of particular relevance
for the present study, of having a relatively flat dose-response
curve. We therefore decided to use the rat hepatocyte system
as it provides a robust reproducible model for examining
growth factor activity and we have previous experience of its
reliability in assessing the biological activity of other EGF
receptor ligands.12 It provides a highly reproducible dose-
response curve and is of particular value for examining
growth factor activity in intestinal juice as hepatocytes are not
adversely affected by normal small intestinal luminal
contents.14 It cannot be used however to assess changes in cell
number as under the conditions used, hepatocytes complete
cell DNA synthesis but cell division occurs infrequently and no
net increase in cell number is seen.16
There are many well validated acute models of gastric
injury. We chose the indomethacin/restraint model as our in
vivo assay system because peptic ulceration due to non-
steroidal anti-inflammatory drugs is a major source of
morbidity and mortality in humans17 and we have previously
used it to examine the influence of peptic digestion on the
EGF molecule.18
TGF-α is produced in the mucosa throughout the gastro-
intestinal tract1 and is synthesised as a 160 amino acid precur-
sor molecule that spans the cell membrane. Subsequent expo-
sure of the external domain to specific proteases releases the
soluble mature 50 amino acid form19 which has a molecular
weight of 5546 and includes three Cys-Cys double bonds.
TGF-α shares 33% sequence homology with EGF and has
nearly identical biological activity, acting through the same
EGF receptor (EGF-R), also known as the erbB-1 receptor.
There is continuing controversy as to whether erbB-1
receptors are present on the apical (luminal) surface in addi-
tion to the basolateral membrane of the normal bowel.20–23
However, there is general agreement that luminal administra-
tion of erbB-1 ligands can stimulate growth and repair, acting
via the luminal surface, when administered to the damaged
bowel of both rats24 and humans.25
Our studies have shown that, under acidic conditions, pep-
sin cleaved the 43Cys-44Glu bond of the TGF-α molecule.
Several isoforms of pepsin exist which differ slightly in their
preferred substrate specificity and pH profile.26 However, we
have previously shown that the vast majority of gastric
proteolytic activity is dependant on an acidic pH with proteo-
lytic activity markedly diminishing when pH rises to 4 or
above.18 Inactivation of pepsin therefore almost certainly
explains the finding of the change in predominant form to
TGF-α1–50 which was seen in patients taking PPIs or during
intragastric neutralisation. Our in vitro study on the stability
of native TGF-α in acid pepsin gave similar results to those
found using recombinant TGF-α. However, caution should
always be shown before assuming recombinant peptides
behave in an identical fashion to their native forms.
The concentration of TGF-α in gastric juice found in our
studies (about 200 ng/l) is similar to that reported by others,27
being about one third of that of EGF (500 ng/l). The function
of TGF-α in gastric juice is unclear although several lines of
evidence suggest pathophysiological relevance: TGF-α is a
potent stimulant of proliferation of several gastrointestinal
cell lines in vitro,2–5 protects against injury and/or stimulates
repair in several different animal models of gastrointestinal
injury (for example, see Konturek and colleagues7 and
Romano and colleagues8), and physiological concentrations of
gastric juice TGF-α are probably sufficient to stimulate prolif-
eration of human gastric explants.28 In addition, pathophysi-
ological relevance for this concentration of TGF-α in gastric
juice is supported by the finding that sialadenectomy of rats
reduces the amount of EGF present in gastric juice by about
60% (approximately 300 ng/l), which is similar to the receptor
ligand contribution from TGF-α (200 ng/l), causing an
increased susceptibility to noxious agents with increased
ulceration and delayed healing.29 Taken together, these results
suggest an important role for gastric juice TGF-α, working in
combination with EGF, in maintaining epithelial integrity. It is
also important to note that virtually all previous studies
measuring TGF-α in gastric juice have used immunoassays.
Our finding that the immunoreactivity of the digested form is
reduced is therefore important as it may lead to underestima-
tion of gastric levels of TGF-α under acidic conditions unless
appropriate corrections are made.
Indomethacin causes damage to the gastrointestinal tract
by several mechanisms, including reduction of mucosal
prostaglandin levels, reduction of mucosal blood flow,
stimulating neutrophil activation, and possibly also stimulat-
ing apoptosis.30 It is likely that many of these mechanisms will
be influenced by the presence of the TGF-α. Both forms of
TGF-α significantly reduced indomethacin induced gastric
damage when administered at both 0.18 and 0.9 µmol/kg/h.
The lower dose of TGF-α probably did not affect gastric acid
secretion31 but the higher dose may have done so because 1.8
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µmol/kg/h of TGF-α 1–50, administered intravenously, decreases
gastric acid secretion by 72%.31 This may be relevant to the
mechanism by which TGF-α decreased gastric damage in our
rat model as we have previously shown the damage to be acid
dependant.15 Cleavage of the terminal seven amino acids of
TGF-α caused a 3–5 fold reduction in its ability to reduce
injury in this model, which was similar to the reduction in
activity found using the in vitro assay. The results of the in vivo
study are likely to be due to reduced interaction of circulating
TGF-α1–43 with its receptors on gut cells. Alteration in the
circulating half-life of the truncated form remains a possibility
but is much less likely in view of the comparable data from in
vitro studies.
Tam and colleagues32 examined which areas of the TGF-α
molecule played a key role in its interaction with the erbB-1
receptor. They found that the seven C terminal amino acids
have a major influence on its ability to bind and stimulate
mitogenesis of rat kidney fibroblasts, with TGF-α1–43 having
only 1/1000 of the activity of TGF1–50. This is a much lower level
of bioactivity than found in our studies although Tam et al did
not perform any in vivo studies. Importantly, in their studies,
TGF-α1–43 was produced using solid phase peptide synthesis,
rather than recombinant technology, and the authors specifi-
cally mention the difficulties of obtaining correct refolding of
TGF-α1–43 using this method. The different cell lines used (rat
kidney fibroblasts v primary rat hepatocytes) may also be rel-
evant.
Recent studies examining the effect of knockout of EGF-R
ligands suggest that EGF-R ligands function in a synergistic
fashion with deletion of an individual member having
relatively little effect on phenotype33 34 whereas multiple
knockouts or deletion of the EGF-R itself resulting in
profound effects on the gut.35 36 The current series of studies
suggest that changing the size of the TGF-α molecule from the
truncated form to TGF-α1–50, as found in most patients taking
PPIs, is biologically equivalent to a 2–3 fold increase in TGF-α
concentration. We have previously shown a similar reduction
in gastric EGF bioactivity in response to acid and pepsin.18 The
current findings therefore support the idea that luminal pH is
likely to have a major influence on multiple luminal growth
factors within the gastric juice. This may well have relevance
to pro-healing activity (as seen with acid suppressants) and
also conditions associated with abnormal growth, such as
patients with pernicious anaemia or severe atrophic pangas-
tritis (who fail to make gastric acid) and are known to have an
increased risk of development of gastric carcinoma.37 Further
studies appear warranted.
. . . . . . . . . . . . . . . . . . . . .
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